Welcome to our dedicated page for Nuvation Bio SEC filings (Ticker: NUVB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Nuvation Bio Inc. filings document the regulatory record of a public oncology company with Class A common stock listed on the New York Stock Exchange. The company's 8-K disclosures cover operating and financial results, material agreements, clinical and regulatory updates for taletrectinib and safusidenib, pipeline decisions involving its drug-drug conjugate program, and other material-event disclosures.
Proxy materials describe board elections, auditor ratification, executive compensation votes, shareholder voting procedures, and governance matters. Capital-structure filings identify the company's registered securities, including Class A common stock and historical warrant-related disclosures, while Form 25 records document removal of a warrant class from exchange listing and registration.
Nuvation Bio Inc. reported the results of its 2026 Annual Meeting of Stockholders. Holders of 389,931,796 shares were present in person or by proxy, representing 83.6% of the Class A Common Stock and 100% of the Class B Common Stock outstanding as of March 25, 2026, which constituted a quorum.
Stockholders elected Class A directors Robert B. Bazemore, Jr. and Robert Mashal, M.D., and Class B director Kim Blickenstaff to serve until the 2029 annual meeting and until their successors are elected and qualified. Stockholders also ratified KPMG LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.
On an advisory basis, stockholders approved the compensation of the Company’s named executive officers as disclosed in the April 10, 2026 proxy statement. All three proposals received sufficient votes for approval.
Nuvation Bio Inc. reported the results of its 2026 Annual Meeting of Stockholders. Holders of 389,931,796 shares were present in person or by proxy, representing 83.6% of the Class A Common Stock and 100% of the Class B Common Stock outstanding as of March 25, 2026, which constituted a quorum.
Stockholders elected Class A directors Robert B. Bazemore, Jr. and Robert Mashal, M.D., and Class B director Kim Blickenstaff to serve until the 2029 annual meeting and until their successors are elected and qualified. Stockholders also ratified KPMG LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.
On an advisory basis, stockholders approved the compensation of the Company’s named executive officers as disclosed in the April 10, 2026 proxy statement. All three proposals received sufficient votes for approval.
Nuvation Bio Inc. director Vernon W. Anthony received a grant of stock options covering 123,397 shares of Class A common stock. The options have an exercise price of $4.79 per share and expire on May 20, 2036. All 123,397 shares subject to the option will vest on the earlier of May 21, 2026 or the next shareholder annual meeting, provided he remains in continuous service through that date. Following this compensation-related award, he holds 123,397 options directly, and the filing does not report any open-market buying or selling.
Nuvation Bio Inc. director Robert Mashal received a grant of stock options covering 123,397 shares of Class A common stock at an exercise price of $4.79 per share. These options vest 100% on the earlier of May 21, 2026 or the next shareholder annual meeting, contingent on his continuous service. Following the grant, he holds options for 123,397 shares directly, expiring on May 20, 2036.
Nuvation Bio Inc. director Kathryn E. Falberg received a grant of stock options covering 123,397 shares of Class A common stock at an exercise price of $4.79 per share. The options vest 100% on the earlier of May 21, 2026 or the next shareholder annual meeting, subject to her continuous service, and expire on May 20, 2036. Following this award, she holds 123,397 derivative securities directly.
Nuvation Bio Inc. reported that director Kim D. Blickenstaff received a grant of stock options. The award covers 123,397 options to buy Class A common stock at an exercise price of $4.79 per share, expiring on May 20, 2036.
All of the options vest 100% on the earlier of May 21, 2026 or the next shareholder annual meeting, as long as the director remains in continuous service. Following this grant, the filing shows 123,397 derivative securities held directly, with no open‑market purchases or sales reported.
Nuvation Bio Inc. director Robert B. Bazemore received a stock option grant covering 123,397 shares of Class A common stock. The option has an exercise price of $4.79 per share and expires on May 20, 2036. All shares vest 100% on the earlier of May 21, 2026, or the next shareholder annual meeting, subject to his continuous service. This is a compensation-related award, with no open-market share purchases or sales reported.
Nuvation Bio Inc. director Xiangmin Cui reported receiving a stock option grant on Class A common stock. The award covers 123,397 options with an exercise price of $4.79 per share and expires on May 20, 2036. Following this grant, Cui holds 123,397 derivative securities linked to the company’s Class A common stock.
According to the terms, 100% of the options will vest on the earlier of May 21, 2026 or the next shareholder annual meeting, provided Cui remains in continuous service through that vesting date. This filing reflects a compensation-related acquisition rather than an open-market purchase or sale.
Nuvation Bio Inc. director Xiangmin Cui corrected a prior insider report to show a grant of 76,923 stock options for Class A common stock received on February 27, 2026. These options have a $5.91 exercise price, expire on February 26, 2036, and vest in 24 monthly installments starting from January 1, 2026.
Nuvation Bio reported a strong first quarter of 2026, moving to net income of $5.4 million after a net loss of $53.2 million a year earlier. Total revenue rose to $83.2 million, driven by initial U.S. sales of IBTROZI and a large increase in collaboration and license revenue.
Net product revenue from U.S. sales of IBTROZI (taletrectinib) reached $18.5 million, while collaboration and license agreements revenue climbed to $64.7 million, largely due to an upfront payment under the Eisai agreement. The company ended March 31, 2026 with $533.7 million in cash, cash equivalents, and marketable securities.
Nuvation Bio highlighted updated clinical data showing durable responses for IBTROZI in ROS1‑positive NSCLC and announced acquisition of Japan rights to safusidenib, supporting its global development. Research and development spending increased to $35.0 million, and selling, general and administrative expenses were $38.3 million as the company invests behind its oncology portfolio.
Nuvation Bio Inc. reported a sharp turnaround for the quarter ended March 31, 2026, posting net income of $5.4M compared with a loss of $53.2M a year earlier. Total revenue rose to $83.2M from $3.1M, driven by U.S. IBTROZI product sales and a major taletrectinib license deal with Eisai.
Product revenue reached $18.5M, while collaboration and license revenue increased to $64.7M, including about $58.7M of upfront license revenue from Eisai. Operating cash flow improved to a positive $5.1M. The company ended the quarter with $533.7M in cash, cash equivalents and marketable securities and continues to invest heavily in research and development and commercializing IBTROZI.